NCT00630942

Minocycline in Primary Sclerosing Cholangitis (PSC)

Open Label Pilot Study Evaluating Minocycline in Patients With Primary Sclerosing Cholangitis (PSC)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to see how safe and effective minocycline is in the treatment of Primary Sclerosing Cholangitis (PSC).

Detailed description

The purpose of the study is to determine the safety profile of minocycline in patients with PSC and to compare the effects of minocycline on the baseline values of the following parameters: symptoms of pruritus and fatigue, liver biochemistries, Mayo Risk Score, the development of clinical progression and complications of liver disease.

Conditions

• Primary Sclerosing Cholangitis

Interventions

Type	Name	Description
DRUG	Minocycline	Minocycline 100 mg capsules twice a day before breakfast and before dinner.

Timeline

• Start date: 2003-02-01
• Primary completion: 2007-05-01
• Completion: 2007-05-01
• First posted: 2008-03-07
• Last updated: 2010-12-07

Locations

1 site across 1 country: United States